Noxxon Pharma Ag

Aptarion Biotech Ag

Bayer Schering Pharma Ag

Cnm Technologies Gmbh

Aptarion Biotech

Vater, Axel

Bundesrepublik Deutschland, Vertr. D.d. Bundes- Ministerium F. Wirtschaft- Und Technologie, Dieses Vertr. D.d. Präs. D. Phys.-techn. Bundesanstalt

Axel Vater

Sven Klussmann

Christian Maasch

Klaus Buchner

Kai Hohlig

Werner Purschke

Florian Jarosch

Dirk Eulberg

Dirk Zboralski

Klaus Schiene

Gregor Bahrenberg

Kai Licha

Michael Schirner

Steffen Helmling

Albert Schnieders

Sonja Vollmer

Bernd Eschgfäller

Ingo Röhl

Clemens Gillen

Simone Sell

Ingo Rohl

Mathias Bell

Elisabeth Moyroud

Sandra Stark

Thorsten Ruppert

Nikolaus Meyerbröker

D Lucas Bethge

Kai HÖHLIG

The present invention is related to an L-nucleic acid molecule capable of binding to human CXCL8, wherein the L-nucleic acid molecule comprises a central stretch of nucleotides, wherein the central stretch of nucleotides comprises a nucleotide sequence of 5'-GG A AGU ACGUGGA AAGCCRA(Xu)RAGUGUGUCCCG-3′[SEQ. ID. NO: 27], wherein Xu is U or absent.

CXCL8 binding nucleic acids

The present invention is related to a nucleic acid molecule capable of binding to human C5a, wherein the nucleic acid molecule comprises a central stretch of nucleotides, wherein the central stretch of nucleotides comprises a nucleotide sequence of 5' AUGnGGUGKUnnRGGGHUGUKGGGnGnCGACGCA 3′ [SEQ ID NO: 61], wherein nis U or dU, nis G or dG, nis A or dA, nis U or dU, nis U or dU and G, A, U, C, H, K, and R are ribonucleotides, and dU, dG and dA are 2′-deoxyribonucleotides.

C5a binding nucleic acids

The present invention is related to a nucleic acid molecule capable of binding to human C5a, wherein the nucleic acid molecule comprises a central stretch of nucleotides, wherein the central stretch of nucleotides comprises a nucleotide sequence of 5' AUGnGGUGKUnnRGGGHUGUKGGGnGnCGACGCA 3&#x2032; [SEQ ID NO: 61], wherein nis U or dU, nis G or dG, nis A or dA, nis U or dU, nis U or dU and G, A, U, C, H, K, and R are ribonucleotides, and dU, dG and dA are 2&#x2032;-deoxyribonucleotides.

The present invention is related to a molecule capable of inhibiting signaling between SDF-1 and CXCR4 and/or CXCR7, wherein the molecule is for use in a method of modulating the number and/or the spatial distribution of tumor-infiltrating leukocytes in a tumor and/or metastases.

Method of modulating the number and the distribution of tumor-infiltrating leukocytes in tumors

The present invention is related to a method for generating a nucleic acid molecule capable of binding to a target molecule comprising the following steps: a) providing a reference nucleic acid molecule, wherein the reference nucleic acid molecule is capable of binding to the target molecule and wherein the reference nucleic acid molecule comprises a sequence of nucleotides, wherein the sequence of nucleotides comprises n nucleotides; b) preparing a first level derivative of the reference nucleic acid molecule, wherein the first level derivative of the reference nucleic acid molecule differs from the reference nucleic acid molecule at one nucleotide position, wherein the first level derivative is prepared by replacing the ribonucleotide at the one nucleotide position by a 2'-deoxyribonucleotide in case the reference nucleic acid has a ribonucleotide at the nucleotide position and wherein the first level derivative is prepared by replacing the 2&#x2032;-deoxyribonucleotide at the one nucleotide position by a ribonucleotide in case the reference nucleic acid has a 2&#x2032;-deoxyribonucleotide at the nucleotide position and wherein the nucleotide position at which the replacement is made is the modified nucleotide position; and c) repeating step b) for each nucleotide position of the reference nucleic acid molecule, thus preparing a group of first level derivatives of the reference nucleic acid molecule, wherein the group of first level derivatives of the reference nucleic acid molecule consists of n first level derivatives, wherein each of the first level derivatives of the reference nucleic acid molecule differs from the reference nucleic acid molecule by a single nucleotide replacement and wherein each of the first level derivatives of the reference nucleic acid molecule has a single modified nucleotide position which is different from the single modified nucleotide of all of the single modified nucleotide positions of the other first level derivatives of the group of first level derivatives of the reference nucleic acid molecule.

Nucleic acid molecule having binding affinity to a target molecule and a method for generating the same

The present invention relates to the use of a L-nucleic acid as intracellularly active agent.

Use of spiegelmers

Use of spiegelmers to inhibit an intracellular target molecule

The present invention relates to a vasopressin-binding nucleic acid, characterized in that the nucleic acid contains a stretch Box1 and a stretch Box2,

Vasopressin-binding L-nucleic acid

The invention relates to an antagonist for CGRP and amylin, whereby the antagonist is a nucleic acid and said nucleic acid binds to CGRP or amylin. Said nucleic acid preferably comprises an L-nucleotide.

CGRP binding nucleic acids

The present invention concerns the use of indocarbocyanine dyes, in particular indotricarbocyanine dyes for the diagnosis of inflammatory diseases, in particular rheumatoid arthritis, methods of diagnosing inflammatory diseases and an apparatus useful to carry out the method of diagnosing.

Optical imaging of rheumatoid arthritis

Growing community of inventors

Berlin, Germany

Axel Vater